CY1116863T1 - Πρωτεϊνη δεσμευσης υποδοχεα nogo - Google Patents

Πρωτεϊνη δεσμευσης υποδοχεα nogo

Info

Publication number
CY1116863T1
CY1116863T1 CY20151100669T CY151100669T CY1116863T1 CY 1116863 T1 CY1116863 T1 CY 1116863T1 CY 20151100669 T CY20151100669 T CY 20151100669T CY 151100669 T CY151100669 T CY 151100669T CY 1116863 T1 CY1116863 T1 CY 1116863T1
Authority
CY
Cyprus
Prior art keywords
binding protein
receptor binding
nogo receptor
polypeptides
antigen
Prior art date
Application number
CY20151100669T
Other languages
English (en)
Inventor
Sha Mi
John Mccoy
R Blake Pepinsky
Daniel H S Lee
Alexey A Lugovskoy
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of CY1116863T1 publication Critical patent/CY1116863T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)

Abstract

Η εφεύρεση παρέχει Sp35 πολυπεπτίδια και πρωτεΐνες συγχώνευσης αυτών, Sp35 αντισώματα και θραύσματα δέσμευσης αντιγόνου αυτών και νουκλεϊκά οξέα τα οποία κωδικοποιούν τα ίδια. Η εφεύρεση παρέχει επίσης συνθέσεις οι οποίες περιέχουν και μεθόδους δημιουργίας και χρήσης τέτοιων αντισωμάτων Sp35, θραυσμάτων δέσμευσης αντιγόνου αυτών, Sp35 πολυπεπτιδίων και πρωτεϊνών συγχώνευσης αυτών.
CY20151100669T 2003-03-19 2015-07-29 Πρωτεϊνη δεσμευσης υποδοχεα nogo CY1116863T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45575603P 2003-03-19 2003-03-19
US48024103P 2003-06-20 2003-06-20
US49205703P 2003-08-01 2003-08-01
EP10171533.2A EP2248899B8 (en) 2003-03-19 2004-03-17 NOGO receptor binding protein

Publications (1)

Publication Number Publication Date
CY1116863T1 true CY1116863T1 (el) 2017-04-05

Family

ID=33102167

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101101094T CY1111097T1 (el) 2003-03-19 2010-11-30 Πρωτεϊνη δεσμευσης του υποδοχεα nogo
CY20151100669T CY1116863T1 (el) 2003-03-19 2015-07-29 Πρωτεϊνη δεσμευσης υποδοχεα nogo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20101101094T CY1111097T1 (el) 2003-03-19 2010-11-30 Πρωτεϊνη δεσμευσης του υποδοχεα nogo

Country Status (27)

Country Link
US (5) US7785829B2 (el)
EP (3) EP2902491A1 (el)
JP (3) JP5341311B2 (el)
KR (1) KR101106441B1 (el)
AT (1) ATE479754T1 (el)
AU (2) AU2004223464C1 (el)
BR (1) BRPI0408501A (el)
CA (1) CA2519227C (el)
CY (2) CY1111097T1 (el)
DE (1) DE602004028916D1 (el)
DK (2) DK2248899T3 (el)
EA (1) EA010055B1 (el)
ES (1) ES2537015T3 (el)
GE (1) GEP20094629B (el)
HK (3) HK1146297A1 (el)
HU (1) HUE025347T2 (el)
IL (1) IL170721A (el)
IS (1) IS2786B (el)
MX (1) MXPA05009913A (el)
NO (1) NO336530B1 (el)
NZ (1) NZ607886A (el)
PL (3) PL2248899T3 (el)
PT (2) PT1606409E (el)
RS (1) RS54160B1 (el)
SI (2) SI1606409T1 (el)
UA (1) UA87106C2 (el)
WO (1) WO2004085648A2 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010055B1 (ru) 2003-03-19 2008-06-30 Байоджен Айдек Ма Инк. ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, КОДИРУЮЩАЯ ПОЛИПЕПТИД Sp35, ПОЛИПЕПТИД Sp35 И СПОСОБЫ ПРИМЕНЕНИЯ НУКЛЕИНОВОЙ КИСЛОТЫ И ПОЛИПЕПТИДА
KR101239542B1 (ko) * 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 탈수초화를 수반하는 병의 치료
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
EP1681565B1 (de) * 2005-01-14 2011-07-06 Abbott GmbH & Co. KG Zellulärer RhoGTPase Aktivierungs-Assay
WO2007008547A2 (en) * 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
EP1940460A4 (en) * 2005-10-27 2009-08-12 Biogen Idec Inc OLIGOD DRO CYTEN MYELIN GLYCOPROTEIN COMPOSITIONS AND USES THEREOF
US20090246189A1 (en) * 2005-11-04 2009-10-01 Biogen Idec Ma Inc. And Mclean Hospital Methods for Promoting Neurite Outgrowth and Survival of Dopaminergic Neurons
NZ598421A (en) 2005-12-02 2013-11-29 Biogen Idec Inc Treatment of Conditions Involving Demyelination
JP2009544703A (ja) 2006-07-24 2009-12-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
AU2007321817A1 (en) * 2006-11-17 2008-05-22 Novartis Ag Lingo binding molecules and pharmaceutical use thereof
GEP20125693B (en) 2007-01-09 2012-11-26 Biogen Idec Inc Sp35 antibodies and usage thereof
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US20100297121A1 (en) * 2007-10-11 2010-11-25 Biogen Idec Ma Inc. Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists
US20110123553A1 (en) * 2007-11-08 2011-05-26 Biogen Idec Ma Inc. Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
JP2012048656A (ja) * 2010-08-30 2012-03-08 Canon Inc 画像処理装置、画像処理方法
MX2014013950A (es) 2012-05-14 2015-02-17 Biogen Idec Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
JP2015534564A (ja) 2012-10-09 2015-12-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 脱髄障害の治療のための併用療法および使用
EP3242893A1 (en) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
EP3302465A1 (en) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
JP7149257B2 (ja) 2016-07-13 2022-10-06 バイオジェン・エムエイ・インコーポレイテッド Ｌｉｎｇｏ－１アンタゴニストの投与計画及び脱髄障害の処置のための使用
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2020185750A1 (en) 2019-03-11 2020-09-17 Biogen Ma Inc. Pharmaceutical compositions containing anti-lingo-1 antibodies

Family Cites Families (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) * 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4716111A (en) * 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4694778A (en) * 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5892019A (en) * 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1892296A1 (en) 1988-09-02 2008-02-27 Dyax Corporation Generation and selection of recombinant varied binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
EP0474727B1 (en) * 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
US5413923A (en) * 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) * 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) * 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DE69127749T2 (de) 1990-03-20 1998-04-16 Univ Columbia Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5219837A (en) * 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5532351A (en) 1990-07-12 1996-07-02 Arch Development Corporation Nucleic acid sequences encoding OMGP
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) * 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) * 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DK0574395T3 (da) 1990-11-09 2002-10-07 Stephen D Gillies Cytokin-immunkonjugater
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE164395T1 (de) * 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
CA2108147C (en) * 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
AU2238292A (en) 1991-06-14 1993-01-12 Xoma Corporation Microbially-produced antibody fragments and their conjugates
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
CA2128862C (en) * 1992-02-11 2008-05-20 Jonathan G. Seidman Homogenotization of gene-targeting events
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0627932B1 (en) * 1992-11-04 2002-05-08 City Of Hope Antibody construct
DE669986T1 (de) * 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
DE69408541T2 (de) * 1993-11-23 1998-08-06 Genentech Inc Kinaserezeptoraktivierungstest
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
DE4415539C2 (de) * 1994-05-03 1996-08-01 Osama Dr Dr Med Omer Pflanzen mit virustatischer und antiviraler Wirkung
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
WO2001004311A1 (en) 1999-07-07 2001-01-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1020427B1 (en) 1994-10-25 2003-10-01 Toyama Chemical Co., Ltd. Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof
US5770577A (en) 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6280964B1 (en) * 1995-04-14 2001-08-28 The Regents Of The University Of California Binding sites for phosphotyrosine binding domains
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
EP0873363B1 (en) 1995-06-14 2010-10-06 The Regents of The University of California High affinity human antibodies to tumor antigens
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
IT235676Y1 (it) 1995-07-27 2000-07-12 Felice Gaudioso Allestimenti per lo svolgimento del gioco wormhole action match.
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
JP2978435B2 (ja) * 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6455277B1 (en) 1996-04-22 2002-09-24 Amgen Inc. Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
JP2000501416A (ja) 1996-04-26 2000-02-08 ユニバーシティー オブ オタワ ニューロン病を治療し予防するための、治療法および薬物のスクリーニング法
US5611016A (en) * 1996-06-07 1997-03-11 Lucent Technologies Inc. Dispersion-balanced optical cable
JP2000514420A (ja) 1996-06-25 2000-10-31 セファロン・インコーポレイテッド 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ―２５２ａ誘導体の使用
DE69740038D1 (el) * 1996-07-12 2010-12-16 Genentech Inc
ZA976326B (en) 1996-07-19 1998-02-03 Amgen Inc Analogs of cationic proteins.
CA2264966A1 (en) 1996-09-11 1998-03-19 The General Hospital Corporation Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein
CN1233963A (zh) 1996-09-13 1999-11-03 有限会社最先端医学研究所 神经营养因子的眼科用组合物、视神经机能障碍治疗药和视神经机能障碍治疗方法
US6420140B1 (en) * 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20070213290A1 (en) 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
ATE387495T1 (de) 1996-12-03 2008-03-15 Amgen Fremont Inc Vollkommen humane antikörper die egfr binden
RO120148B1 (ro) * 1997-03-14 2005-09-30 Idec Pharmaceuticals Corporation Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
US20020112251A1 (en) * 1997-08-04 2002-08-15 Mccarthy Sean A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses
AU8768798A (en) 1997-08-04 1999-02-22 Millennium Pharmaceuticals, Inc. Tango-78, tango-79, and tango-81 nucleic acid molecules and polypeptides
KR100502596B1 (ko) 1997-09-17 2005-07-22 제넨테크, 인크. 분비 폴리펩티드와 막횡단 폴리펩티드 및 이들을 코딩하는핵산
US6974689B1 (en) * 1997-09-18 2005-12-13 Genentech, Inc. Nucleic acid encoding PRO211 polypeptides
DK1205546T3 (da) * 1997-10-24 2006-04-03 Genentech Inc Polypeptider og nucleinsyrer kodende derfor
FR2776661B1 (fr) 1998-03-26 2002-04-05 Centre Nat Rech Scient Polypeptide immunoreactif du recepteur trka du ngf et utilisations
US7282482B2 (en) 1998-04-08 2007-10-16 The Regents Of The University Of California NGF for the prevention of demyelination in the nervous system
IL141535A0 (en) 1998-09-16 2002-03-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU774367C (en) 1998-11-06 2005-04-21 University Of Zurich Nucleotide and protein sequences of nogo genes and methods based thereon
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
CA2383592A1 (en) 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040067490A1 (en) * 2001-09-07 2004-04-08 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CA2373721C (en) * 1999-07-02 2013-10-15 Genentech, Inc. Compounds that bind her2
AU6181300A (en) * 1999-07-29 2001-02-19 Helix Research Institute Liver cancer-associated genes
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
JP2003527089A (ja) * 1999-08-17 2003-09-16 インサイト・ゲノミックス・インコーポレイテッド 膜関連タンパク質
US6461414B1 (en) 1999-10-29 2002-10-08 Baker Hughes Incorporated Foam monitoring and control system
EP1661997A1 (en) 1999-12-01 2006-05-31 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
ES2341842T3 (es) 2000-01-12 2010-06-29 Yale University Bloqueo del crecimiento axonal mediado por el receptor de nogo.
AU2001228212A1 (en) 2000-01-18 2001-07-31 Mcgill University Beta-turn peptidomimetic cyclic compounds
CA2398396A1 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides
WO2001055317A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001059063A2 (en) 2000-01-31 2001-08-16 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001055447A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
EP1254269A4 (en) 2000-02-03 2004-10-27 Nuvelo Inc METHODS AND MATERIALS IN CONNECTION WITH POLYPEPTIDES AND POLYNUCLEOTIDS, WHICH LIKE NEURONAL GUIDE MOLECULES
US6800607B2 (en) 2000-02-29 2004-10-05 Ltt Bio-Pharma Co., Ltd. Modified BDNF
CN101289511A (zh) * 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
WO2002000677A1 (en) * 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6430914B1 (en) 2000-06-29 2002-08-13 Foster Wheeler Energy Corporation Combined cycle power generation plant and method of operating such a plant
US20040010118A1 (en) 2000-08-16 2004-01-15 Zerhusen Bryan D. Novel proteins and nucleic acids encoding same
IL154725A (en) 2000-09-13 2003-12-23 Smithkline Beecham Corp Polynucleotides encoding secreted polypeptides
EP1349930A2 (en) 2000-10-05 2003-10-08 Curagen Corporation Human proteins, polynucleotides encoding them and methods of using the same
AU1153902A (en) * 2000-10-06 2002-04-15 Univ Yale Nogo receptor homologs
EP1340088B1 (en) * 2000-11-17 2007-01-17 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20030216558A1 (en) 2000-12-22 2003-11-20 Morris David W. Novel compositions and methods for cancer
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
NZ527283A (en) 2001-01-29 2006-03-31 Biogen Idec Inc Modified antibodies and methods of use
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
FI111522B (fi) * 2001-05-07 2003-08-15 Marioff Corp Oy Palontorjuntalaitteisto ja palontorjuntalaitteiston käyttölähde
CA2448073A1 (en) 2001-06-04 2002-12-12 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030162734A1 (en) 2001-06-28 2003-08-28 Miller Carol A. Modulation of DENN-MADD expression and interactions for treating neurological disorders
US7223558B2 (en) * 2001-07-11 2007-05-29 Bristol-Myers Squibb Company Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
US20030226155A1 (en) 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20050123990A1 (en) 2001-09-26 2005-06-09 Incyte Corporation Membrane associated proteins
WO2003061559A2 (en) 2001-10-12 2003-07-31 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of erbb2 and uses therefor
WO2003035833A2 (en) 2001-10-22 2003-05-01 Exelixis, Inc. Modifier of the p53 pathway and methods of use
US7309485B2 (en) 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
WO2003054152A2 (en) 2001-12-10 2003-07-03 Nuvelo, Inc. Novel nucleic acids and polypeptides
US20030215849A1 (en) 2002-03-01 2003-11-20 Marcia Belvin PDPK1s as modifiers of the p53 pathway and methods of use
JP4761710B2 (ja) 2002-04-05 2011-08-31 アムジェン インコーポレイテッド 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
AU2003264033A1 (en) 2002-08-10 2004-02-25 Biogen Idec Ma Inc. Nogo receptor antagonists
ATE549033T1 (de) 2002-09-06 2012-03-15 Amgen Inc Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
US20040186044A1 (en) 2002-11-06 2004-09-23 Cosgaya Jose Miguel Modulation of myelination by interaction with P75 and TRK receptors
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
EA010055B1 (ru) 2003-03-19 2008-06-30 Байоджен Айдек Ма Инк. ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, КОДИРУЮЩАЯ ПОЛИПЕПТИД Sp35, ПОЛИПЕПТИД Sp35 И СПОСОБЫ ПРИМЕНЕНИЯ НУКЛЕИНОВОЙ КИСЛОТЫ И ПОЛИПЕПТИДА
CA2535007A1 (en) 2003-08-07 2005-02-24 Biogen Idec Ma Inc. Nogo receptor antagonists
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US7205387B2 (en) 2003-08-28 2007-04-17 Agency For Science, Technology And Research Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
EP1663278A4 (en) 2003-08-28 2009-07-29 Biorexis Pharmaceutical Corp EPO MIMETIC PEPTIDES AND FUSION PROTEINS
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
ES2378767T3 (es) 2003-12-23 2012-04-17 Crucell Holland B.V. Molécula de unión humana contra CD1a
AU2005213965B2 (en) 2004-02-12 2009-11-19 Lexicon Pharmaceuticals, Inc. Gene disruptions, compositions and methods relating thereto
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
US20050214288A1 (en) * 2004-03-26 2005-09-29 Human Genome Sciences, Inc. Antibodies against Nogo receptor
JP4969440B2 (ja) * 2004-04-08 2012-07-04 デビッド， ビー． エイガス， 疼痛治療のためのＥｒｂＢアンタゴニスト
KR101239542B1 (ko) * 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 탈수초화를 수반하는 병의 치료
US20060009288A1 (en) 2004-07-07 2006-01-12 Devos John A Conveying information to an interrogator using resonant and parasitic radio frequency circuits
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AR054260A1 (es) 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
EP1879917A2 (en) 2005-04-29 2008-01-23 Wyeth Nogo receptor functional motifs and peptide mimetics related thereto and methods of using the same
CA2609077A1 (en) 2005-05-16 2006-12-28 Mcgill University Lgi, lingo and p75ntr family members: novel modulators of neuronal growth
AR053401A1 (es) 2005-06-06 2007-05-02 Wyeth Corp Anticuerpos monoclonales anti- trkb y usos de los mismos
WO2006133353A2 (en) 2005-06-08 2006-12-14 The University Of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics
AU2005332949A1 (en) 2005-06-16 2006-12-21 University Technologies International Inc. A treatment for short bowel syndrome
WO2007008547A2 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1940460A4 (en) 2005-10-27 2009-08-12 Biogen Idec Inc OLIGOD DRO CYTEN MYELIN GLYCOPROTEIN COMPOSITIONS AND USES THEREOF
US20090246189A1 (en) 2005-11-04 2009-10-01 Biogen Idec Ma Inc. And Mclean Hospital Methods for Promoting Neurite Outgrowth and Survival of Dopaminergic Neurons
NZ598421A (en) 2005-12-02 2013-11-29 Biogen Idec Inc Treatment of Conditions Involving Demyelination
WO2007092777A2 (en) 2006-02-02 2007-08-16 Wyeth Cloning, characterization, and application of tnfrsf19 in neurological disorders
US7693698B2 (en) * 2006-02-03 2010-04-06 Wyeth Llc Method for identifying or designing a candidate agent that interacts with LINGO-1 polypeptide using a LINGO-1 three-dimensional structure
WO2007098283A2 (en) 2006-02-27 2007-08-30 Biogen Idec Ma Inc. Use of antagonists of maif receptor complex molecules and neurotrophic factors for treatment of neurological diseases and disorders
JP2009544703A (ja) * 2006-07-24 2009-12-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
AU2007321817A1 (en) 2006-11-17 2008-05-22 Novartis Ag Lingo binding molecules and pharmaceutical use thereof
GEP20125693B (en) 2007-01-09 2012-11-26 Biogen Idec Inc Sp35 antibodies and usage thereof
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US20100297121A1 (en) * 2007-10-11 2010-11-25 Biogen Idec Ma Inc. Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists
US20110123553A1 (en) 2007-11-08 2011-05-26 Biogen Idec Ma Inc. Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination
EP2307042B1 (en) 2008-06-25 2014-03-26 H. Lundbeck A/S Modulation of the trpv : vps10p-domain receptor system for the treatment of pain
KR20110044991A (ko) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＮＦ-α 길항제 다-표적 결합 단백질
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
GB2477705B (en) 2008-11-17 2014-04-23 Veracyte Inc Methods and compositions of molecular profiling for disease diagnostics
FR2958293B1 (fr) 2010-04-01 2014-09-26 Centre Nat Rech Scient Outils pour l'identification de ligands de lingo-1,lingo-2, lingo-3 et lingo-4, et utilisations
MX2014013950A (es) 2012-05-14 2015-02-17 Biogen Idec Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.

Also Published As

Publication number Publication date
EP2248899B1 (en) 2015-05-06
NO336530B1 (no) 2015-09-21
PT1606409E (pt) 2010-12-20
US20150177240A1 (en) 2015-06-25
MXPA05009913A (es) 2005-11-04
AU2004223464A1 (en) 2004-10-07
EP1606409B1 (en) 2010-09-01
CY1111097T1 (el) 2015-06-11
US8932821B2 (en) 2015-01-13
NZ607886A (en) 2014-09-26
IS8016A (is) 2005-09-08
AU2004223464C1 (en) 2010-09-23
HUE025347T2 (en) 2016-02-29
SI2248899T1 (sl) 2015-07-31
AU2004223464A2 (en) 2004-10-07
ES2537015T3 (es) 2015-06-01
HK1085764A1 (en) 2006-09-01
IL170721A (en) 2011-07-31
PL378582A1 (pl) 2006-05-02
WO2004085648A2 (en) 2004-10-07
RS54160B1 (sr) 2015-12-31
CA2519227C (en) 2013-12-03
SI1606409T1 (sl) 2011-01-31
DK2248899T3 (en) 2015-06-29
JP2013138688A (ja) 2013-07-18
DK1606409T3 (da) 2011-01-03
US20100204304A1 (en) 2010-08-12
JP5341311B2 (ja) 2013-11-13
HK1146297A1 (en) 2011-05-20
US20070059793A1 (en) 2007-03-15
WO2004085648A3 (en) 2004-11-18
JP2010154861A (ja) 2010-07-15
PT2248899E (pt) 2015-09-23
PL1606409T3 (pl) 2011-02-28
ATE479754T1 (de) 2010-09-15
EA200501480A1 (ru) 2006-02-24
EP2248899B8 (en) 2015-07-15
UA87106C2 (uk) 2009-06-25
EP2248899A1 (en) 2010-11-10
EP2902491A1 (en) 2015-08-05
CA2519227A1 (en) 2004-10-07
JP2007524370A (ja) 2007-08-30
US20130287693A1 (en) 2013-10-31
EP1606409A2 (en) 2005-12-21
EA010055B1 (ru) 2008-06-30
KR20050110012A (ko) 2005-11-22
US8153580B2 (en) 2012-04-10
US20120230979A1 (en) 2012-09-13
NO20054836L (no) 2005-10-19
US7785829B2 (en) 2010-08-31
AU2010202636A1 (en) 2010-07-15
PL2248899T3 (pl) 2015-10-30
US8765662B2 (en) 2014-07-01
RS20050709A (en) 2007-11-15
HK1211618A1 (en) 2016-05-27
GEP20094629B (en) 2009-03-10
KR101106441B1 (ko) 2012-01-18
DE602004028916D1 (de) 2010-10-14
BRPI0408501A (pt) 2006-03-14
IS2786B (is) 2012-05-15
AU2004223464B2 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
CY1116863T1 (el) Πρωτεϊνη δεσμευσης υποδοχεα nogo
IS8339A (is) Mótlyf viðtaka NOGO
NO20050685L (no) NOGO-reseptorantagonister
DE69833014D1 (de) Menschliche toll homologen
EA200600376A1 (ru) Антагонисты nogo-рецептора